Anti-Citrullinated Fibrinogen Immunoglobulin antibody [23H2] (STJ16100952)

SKU:
STJ16100952-100

Shipping:
Free Shipping
Current Stock:
Host: Mouse
Applications: IHC/WB/ELISA
Reactivity: Mouse/Human
Note: STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS.
Short Description: Mouse monoclonal antibody anti-Citrullinated Fibrinogen Immunoglobulin is suitable for use in Immunohistochemistry, Western Blot and ELISA research applications.
Clonality: Monoclonal
Clone ID: 23H2
Conjugation: Unconjugated
Isotype: IgG2b
Formulation: lyophilized in a 10 mM ammonium bicarbonate buffer. Each vial contains 2 mg BSA
Dilution Range: ELISA 1:2000-1:4000
IHC 1:100-1:500
Storage Instruction: Store at 2-8°C upon receipt.
Immunogen: Deiminated murine fibrinogen peptide
Background License is required for use outside research field. Fibrinogen is a protein produced by the liver which helps stop bleeding by helping blood clots to form. Fibrinogen gets deiminated (conversion from arginin to citrullin) by Peptidyl Arginine De i minase (PAD) in inflamed joints in patients that develop rheumatoid arthritis. Citrulline, while being an amino acid, is not built into proteins during protein synthesis, as it is not coded for by DNA, yet several proteins are known to contain citrulline. Proteins that normally contain citrulline residues include myelin basic protein (MBP) , filaggrin, and several histone proteins, while other proteins, like fibrin and vimentin can get deiminated during cell death and tissue inflammation. Patients with rheumatoid arthritis often (at least 80% of them) develop an immune response against proteins containing citrulline. Although the origin of this immune response is not known, detection of antibodies reactive with citrulline containing proteins or peptides is now becoming an important help in the diagnosis of rheumatoid arthritis.

Information sourced from Uniprot.org

12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance